
News|Articles|December 10, 2014
The Need to Study Tissue Biomarkers
Author(s)David L. Rimm MD, PhD
David L. Rimm MD, PhD, from Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
Advertisement
Clinical Pearls
David L. Rimm MD, PhD, Professor of Pathology and of Medicine (Medical Oncology), Director of Pathology Tissue Services, Director of Translational Pathology, Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
- Tissue biomarkers may help to determine which patients will respond to certain drugs.
- Biologically, cancers are different. It is important to be able to determine how patients will respond to treatment.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5



























